CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer

06:27 EDT 18 Apr 2018 | Net Resources International

A major theme of this year’s AACR meeting examines the approaches that aim to further improve the anti-tumour efficacy of...
Read More...

The post CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer appeared first on Drug Development Technology.

More From BioPortfolio on "CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer"